Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

2002 Localized UISS for RCC

A three-group postoperative clinical-outcome classification using pathological T category, Fuhrman grade, and ECOG status.

Evidence-based context for fast calculator use

Purpose:
Reproduce the published localized UISS group for an eligible N0M0 RCC case.
Population:
Surgically resected unilateral renal cell carcinoma without nodal or distant metastasis.
Factors:
1997 pathological T category, Fuhrman nuclear grade, ECOG performance status, Explicit N0M0 confirmation
Reference:
Zisman et al. J Clin Oncol. 2002;20(23):4559-4566.
HomeUISS (UCLA Integrated Staging)
Pin your most used calculators here by clicking the star in the dropdown.

UISS (UCLA Integrated Staging)

Clinical Context & Background

This calculator implements the 2002 Zisman three-group UISS clinical-outcome algorithm for surgically resected, unilateral, nonmetastatic renal cell carcinoma (N0M0). It uses 1997 pathological T category, Fuhrman nuclear grade, and ECOG performance status.
The displayed 5-year disease-specific survival values are observations from the original historical cohort, not individualized contemporary predictions. Do not substitute a modern AJCC T category or WHO/ISUP grade without a validated conversion. Bilateral disease, nonsurgical disease, recurrent-only disease, pediatric tumors, non-RCC tumors, and N-positive or M-positive disease are outside this localized implementation.
Primary Source EvidenceZisman A, et al. J Clin Oncol. 2001;19(6):1649-1657. Zisman A, et al. J Clin Oncol. 2002;20(23):4559-4566. Han KR, et al. J Urol. 2003;170(6 Pt 1):2221-2226.
Formula Logic
2002 localized UISS: Low = T1 + Fuhrman 1-2 + ECOG 0; High = T3 + Fuhrman 2-4 + ECOG >=1, or any T4; Intermediate = every other N0M0 combination.

Reference Data

Localized UISS group2002 criteriaHistorical 5-year DSS
Low riskT1 N0M0, Fuhrman 1-2, ECOG 091.1%
Intermediate riskAll other N0M0 combinations not meeting low or high criteria80.4%
High riskT3 N0M0, Fuhrman 2-4, ECOG >=1; or any T4 N0M054.7%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • After nephrectomy for unilateral RCC when 1997 pathological T category, Fuhrman grade, ECOG status, and N0M0 status are known.
  • Use only when all four required selections are explicit.

How To Interpret

  • Low risk requires T1, Fuhrman 1-2, and ECOG 0.
  • High risk requires T3 with Fuhrman 2-4 and ECOG >=1, or any T4; every other eligible N0M0 combination is intermediate.

What To Do Next

  • Document the source-era variables and the resulting UISS group.
  • Integrate the historical group with current pathology, staging, comorbidity, treatment era, and multidisciplinary follow-up guidance.

Limitations

  • This is the 2002 localized postoperative algorithm using 1997 pathological T and Fuhrman grade.
  • Bilateral, metastatic, nonsurgical, recurrent-only, pediatric, and non-RCC cases are outside scope.
  • Historical cohort outcomes are not individualized predictions or treatment recommendations.

Validated Population

Surgically resected unilateral N0M0 RCC classified with 1997 pathological T category and Fuhrman grade.

Intermediate-risk example

T2, Fuhrman grade 1, ECOG 0, and N0M0 does not meet the low-risk T1 requirement or the high-risk rule, so it is intermediate risk.

Leibovich RCC scoreA separate postoperative clear-cell RCC model.SSIGN scoreA separate postoperative clear-cell RCC model.IMDC metastatic RCC scoreA separate model for advanced/metastatic RCC.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through visible production controls across Low, Intermediate, and High UISS groups.
    • The former literal undefined trace defect was absent.
    • No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/uiss-rcc-2026-08-03.json.

  2. : Local browser remediation verification

    • Ten source-backed cases passed through visible local browser controls across 11 submissions after the shared result-trace correction.
    • The run covered all three UISS risk groups, T1 through T4, Fuhrman grades 1 through 4, both ECOG categories, localized eligibility, metastatic exclusion, historical DSS rows, and reset/repeat behavior.
    • All four visible trace rows displayed defined values with no literal undefined or NaN. The original production findings remain open until deployment and public revalidation.

    Case-level local remediation evidence is retained in validation/browser-production/uiss-rcc.local-remediation.json.

  3. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-ui-console. high: Every valid UISS result displays four bold literal undefined values in the visible trace for applicability, T category, Fuhrman grade, and ECOG. | medium: Production emitted minified React error #418 during route loads and interactions.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/uiss-rcc.json.

  4. : Full validation test

    • 320/320 source-rule, exhaustive combination, UI, outcome, trace, exclusion, malformed-input, registry, report, and isolation checks passed.
    • The renal master panel remains separately verified only for its own implemented components and does not inherit this standalone UISS status.

  5. : Calculation and input-contract correction

    • Replaced the unsupported adverse-feature count with the published 2002 localized UISS decision tree and exact historical 5-year disease-specific survival observations.
    • Removed defaults and coercion; now requires explicit 1997 pathological T, Fuhrman grade, ECOG, and N0M0 selections and rejects N-positive or M-positive disease.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

Leibovich Score (RCC)SSIGN Score (Mayo)IMDC (Heng) Risk Criteria Calculator — Metastatic Renal Cell Carcinoma

Frequently Asked Questions

Can this localized UISS calculator be used for metastatic RCC?

No. N-positive or M-positive disease is explicitly excluded. Use a separately validated model appropriate to the treatment setting, such as IMDC or MSKCC, rather than forcing a localized UISS group.

Can WHO/ISUP grade replace Fuhrman grade?

Not automatically. This version was defined with Fuhrman grade; a modern grade system should not be silently substituted without a validated conversion.

Are the displayed survival percentages personal predictions?

No. They are historical 5-year disease-specific survival observations from the source cohort and do not determine an individual contemporary prognosis or management plan.

Evidence-based oncology decision support. Verify with clinical guidelines.